This inventor holds 27 USPTO granted patents and 3 published patent applications and 5 EPO patents, primarily in Chemokine Modulation. Top assignees: Chemocentryx, Inc., Schering Corporation, Amgen Inc.. Active years: 2003-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
25 out of 219 
2 out of 1,829 
1 out of 2,069 
Years Active: 2003-2022
Areas of Expertise:
Title: The Innovative Contributions of Daniel J. Dairaghi
Introduction
Daniel J. Dairaghi is a prominent inventor based in Palo Alto, California, with an impressive portfolio of 27 patents. His work primarily focuses on the development of novel compounds for pharmaceutical applications, particularly targeting inflammatory diseases. Dairaghi’s contributions play a significant role in advancing medical research and treatment options.
Latest Patents
Among Dairaghi's latest innovations are the patents for heteroaryl sulfonamides and CCR6 compounds. The heteroaryl sulfonamides are designed as potent antagonists of the CCR2 receptor. Animal testing has demonstrated that these compounds are effective in treating inflammation, which is a hallmark disease associated with CCR2. These compounds mainly consist of aryl sulfonamide derivatives, making them valuable for pharmaceutical compositions and methods aimed at treating CCR2-mediated diseases. Furthermore, the CCR6 compounds are beneficial in addressing diseases modulated through the CCR6 receptor, further exemplifying Dairaghi’s focus on inflammatory conditions.
Career Highlights
Throughout his career, Daniel J. Dairaghi has made significant strides in pharmaceutical innovation. He has worked with various reputable companies, including ChemoCentryx, Inc. and Schering Corporation. His experience in these organizations has allowed him to develop groundbreaking technologies and treatments that impact public health.
Collaborations
Dairaghi has collaborated with notable peers in the field, including Andrew M.K. Pennell and Thomas J. Schall. Such collaborations foster innovation and allow for the sharing of expertise, ultimately contributing to successful patent applications and the advancement of pharmaceutical sciences.
Conclusion
Daniel J. Dairaghi's dedication to invention and improvement in the pharmaceutical field is evident in his extensive patent portfolio. His latest work on CCR2 and CCR6 receptor antagonists showcases his commitment to addressing critical health issues. As research in this area continues, Dairaghi's contributions are likely to inspire future innovations in the treatment of inflammation and related diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile